Gastroenteropancreatic neuroendocrine tumours
Research activity is centred on somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, including inoperable and progressive disease with a focus on progression-free survival and treatment response.
- PRRT with lutetium Lu 177 edotreotide
- Well-differentiated GEP-NET
- Somatostatin receptor-positive tumours
The sponsor also studies aggressive Grade 2 and Grade 3 disease within this tumour group, reflecting a strong therapeutic interest in advanced neuroendocrine oncology.
Targeted radiopharmaceutical therapy
Clinical research includes radioligand therapy using 177Lu-edotreotide for receptor-expressing tumours, with attention to tumour control in difficult-to-treat neuroendocrine neoplasms.
- Radiopharmaceutical therapy
- Somatostatin receptor targeting
- Advanced tumour management
This area connects molecular targeting with treatment options for patients whose tumours express somatostatin receptors.
Comparative oncology treatment studies
Trials examine lutetium Lu 177 edotreotide against established standard of care approaches in aggressive GEP-NET, with emphasis on clinically relevant outcomes in refractory disease.
- Best standard of care
- Progressive disease
- Recurrent and refractory tumours
The portfolio addresses patients who have already received prior therapy and still require active treatment options in specialised oncology.
Pediatric solid tumours and lymphoma
Research also extends to pediatric patients with SSTR-positive solid tumours and lymphoma, including recurrent or refractory disease after prior treatment.
- Pediatric oncology
- SSTR-positive solid tumours
- Lymphoma
This reflects interest in applying targeted radiopharmaceutical approaches across both paediatric malignant disease and receptor-positive tumour types.
Safety and pharmacokinetics
One research focus is the evaluation of safety and pharmacokinetics for lutetium Lu 177 edotreotide in children, supporting therapeutic development in younger populations.
- Paediatric dose selection
- Therapy tolerability
- Targeted treatment in children
The sponsor’s clinical interest includes adapting radiopharmaceutical oncology for paediatric use in receptor-positive cancers.
